Background and Purpose-Unstable atherosclerotic plaques are characterized by increased macrophages and reduced smooth muscle cells (SMCs) and collagen content. Endoglin, an accessory transforming growth factor-␤ (TGF␤) receptor, is a modulator of TGF␤ signaling recently found to be expressed on SMCs in atherosclerotic plaques. Its function in plaque SMCs and plaque development is unknown. Early growth response-1 (EGR-1), a transcription factor downstream of TGF␤, stimulates SMC proliferation and collagen synthesis. In atherosclerotic lesions, it is mainly expressed by SMCs. Therefore, we studied the TGF␤, endoglin, and EGR-1 pathway in advanced atherosclerotic plaques in relation to plaque phenotype. Methods-Human carotid atherosclerotic plaques (nϭ103) were collected from patients undergoing carotid endarterectomy. Histologically, plaques were analyzed for plaque characteristics, ie, collagen, macrophage and SMC content, and intraplaque thrombus. Intraplaque endoglin, pSmad (indicative for TGF␤ signaling), EGR-1, and TGF␤ levels were analyzed using Western blots and enzyme-linked immunosorbent assays, respectively. Results -Higher endoglin and EGR-1 protein levels correlated positively with increased plaque collagen levels, increased smooth muscle cell content, and decreased intraplaque thrombi as well as TGF␤ signaling (pSmad). Although EGR-1 overexpression in vitro stimulated collagen synthesis, inhibiting endoglin resulted in lower EGR-1 levels, decreased SMC proliferation, and decreased collagen content. Conclusions-TGF␤ in human atherosclerotic plaques is active and signals through the TGF␤/Smad pathway. For the first time, we show a strong association between endoglin and EGR-1, increased collagen and SMCs expression, decreased levels of intraplaque thrombosis, and a stable plaque phenotype. (Stroke. 2009;40:439-447.)
A therosclerosis is a chronic inflammatory response in the arterial wall. 1 Stable plaques contain more collagen and smooth muscle cells (SMCs), whereas unstable plaques have more macrophages and contain a large lipid core covered with a thin fibrous cap. 2 Unstable plaques are more likely to rupture and cause clinical symptoms, eg, cerebrovascular accidents or myocardial infarction. 3, 4 Therefore, insights into the mechanisms that determine plaque stability are crucial.
Transforming growth factor-␤ (TGF␤) plays an important role in atherogenesis. 5 TGF␤ regulates important cellular processes influencing the development and progression of atherosclerosis such as remodeling of the extracellular matrix and stimulation of SMC proliferation. 6 TGF␤ transduces its signal by binding to TGF␤ Type I and II serine/threonine kinase receptors leading to phosphorylation of Smad proteins. 7 On ligand binding, the Type II receptor will form a complex with ALK5 phosphorylating Smad2/3 or ALK1 and phosphorylate Smad1/5. 8 Endoglin (CD105) is an accessory transmembrane TGF␤ receptor and a modulator of TGF␤ signaling. 9 -13 In human atherosclerotic lesions, the TGF␤ signaling components are detectable in endothelial cells, SMCs, and macrophages and rapidly upregulated during vascular injury. 14 Although TGF␤ is highly expressed in human atherosclerotic lesions, its contribution to lesion development and progression is still unclear. 5, 6, 15 Inhibition of TGF␤ signaling in an athero-sclerotic mouse model significantly inhibits collagen synthesis in atherosclerotic plaques, 16 suggesting an important role for TGF␤ in plaque stabilization. TGF␤-induced collagen synthesis is mediated through increased expression of the transcription factor early growth response-1 (EGR-1). 17 TGF␤-induced pSmad2/3 directly binds to and activates the EGR-1 promoter. 17 Both endoglin and EGR-1 are highly induced shortly after balloon catheter injury 18, 19 and are expressed by SMCs and endothelial cells in advanced atherosclerotic lesions, whereas expression levels in healthy arteries are low. 18,20 -22 Although increased collagen production should improve plaque stabilization, 19 the delicate balance between synthesis and degradation of collagen is more important than synthesis alone. Extracellular matrix metalloproteinase (MMP) inducer (EMMPRIN) stimulates the production of different MMPs and we have previously shown that the 2 isoforms are expressed in atherosclerotic lesions. Although the 58 kD isoform is associated with MMP-9 and an unstable plaque phenotype, EMMPRIN-45kd is associated with MMP-2 and stable plaques. 23 The role of endoglin and EGR-1 in this context and the correlation with matrix degradation and EMMPRIN expression yet remains unknown. In addition to their effect on collagen synthesis, TGF␤ and EGR-1 both stimulate SMC proliferation, although the role of TGF␤ in this context is controversially discussed, because TGF␤ is known for its capacity to inhibit cell growth. 8, 19 Interestingly, endoglin reduces the inhibitory effect of TGF␤ on endothelial cell proliferation. 13 We therefore hypothesized that stable human atherosclerotic plaques contain increased expression levels of endoglin and EGR-1, which mediate the beneficial effects of TGF␤ on plaque stability through induction of collagen synthesis and stimulation of SMC proliferation.
Materials and Methods

Study Design
Athero-Express is a multicenter study combining a biobank of carotid endarterectomy material and patient follow-up data. 24 The study was approved by the local medical ethics committees of each participating center and performed in accordance with institutional guidelines. Informed written consent was obtained from all patients. Baseline characteristics of the patients are depicted in the Table.
Immunohistochemistry
Of each patient (nϭ103), the culprit lesion was divided into sections of 5 m and each plaque was stained for histological determination as described previously. 24 The adjacent segment was used to isolate total protein. Atherosclerotic plaques were stained for endoglin (611314, BD), von Willebrand factor (A0082; Dako), SMC (A2547; Dako), Ki-67 (ab15580; Abcam), and EGR-1 (SC110, Clone 588; Santa Cruz Biotechnology) as previously described. 25 Consecutive slides were stained with CD68 and anti-SMC actin and compared with the localization of EGR-1, endoglin, and pSMAD2 expression.
Protein Expression Analysis
Endoglin, EGR-1, pSmad2 (3104; Cell Signaling Technology), pSmad1/5 (9516; Cell Signaling Technology), and EMMPRIN (SC9753, Clone K-20; Santa Cruz Biotechnology) levels were determined by Western blotting. 8 Twenty micrograms of total protein was loaded on a reduced polyacrylamide gel. Quantification of the bands was carried out using densitometric analysis software, Quantity One (Gel doc; Bio-Rad). Expression levels were correlated to the expression of ␤actin (CloneAC-74; Sigma). A reference sample was loaded on each blot allowing the comparison between runs. Total MMP activities were measured using the Biotrak activity assays RPN2631 for MMP-2 and RPN2634 for MMP-9 (Amersham Biosciences). Total TGF␤1 levels were measured using enzymelinked immunosorbent assay (DB100B; R&D Systems), applying 20 g of total Tripure (Boehringer Mannheim, Indianapolis, Ind) isolated protein (nϭ96).
Effect of mRNA Inhibition of Endoglin on Smooth Muscle Cell Proliferation and Transforming Growth Factor-␤ Signaling
Human aortic SMCs (HA-SMCs, CRL-1999; American Type Culture Collection) were cultured according to the manufacturer. HA-SMCs were infected with adenoviruses expressing Endoglin RNAi or LacZ control at a multiplication of infection of 250. After 16 hours, the cells were washed and allowed to recover for 24 hours, starved overnight, and stimulated with TGF␤ (1 ng/mL) for the indicated times. Cells were washed and total protein was isolated using Tripure Isolation Reagent. Endoglin, EGR-1, pSmad1/5, pSmad2/ pSmad3, procollagen-I (SP1.D8), and Ki-67 (Clone MIB-1; Dako) expression levels were studied using Western blotting as described previously. 25 Migration was measured using a modified Boyden chamber as previously described. 8
Early Growth Response-1 Affects Collagen and CAGA-Reporter Activity
Human embryonic kidney-293 cells (CRL-1573; American Type Culture Collection) were cultured in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin. At approximately 80% confluence, cells were washed twice with phosphate-buffered saline and 0.4 mL serum-free DMEM was added. Human embryonic kidney cells were transfected (Lipofectamine Plus; Invitrogen) with 0.1 g DNA Coll1A2-luciferase (kindly provided by Dr Yutaka Inagaki) or 0.1 g CAGA-Luc, an artificial pSmad3 binding sequence reporter construct, 26 in the absence or presence of different concentrations of an EGR-1 expression plasmid (kindly provided by Professor Dr J. Milbrandt). 27 PGK-LacZ was added as transfection control. After 3 hours, 0.25 mL of 1% FCS, 1% penicillin/streptomycin DMEM medium was added. Two days after transfection, cells were washed twice with phosphate-buffered saline and incubated at room temperature for 15 minutes in 0.2 mL of Lysis buffer (10 mmol/L DTT, 10 mmol/L CDTA, 50% glycerol, 5% Triton X-100, 125 mmol/L Tris, pH 7.8). Fifty microliters of lysate was transferred to a 96-well plate and 50 L of 2ϫ ␤Gal assay buffer (200 mmol/L sodium phosphate, pH 7.3, 2 mmol/L MgCl 2 , 100 mmol/L ␤mercapto, 1.33 
Statistical Analysis
Data are presented as mean and 95% CI. Because our data were not normally distributed, we used the nonparametric Mann-Whitney (for comparison of 2 categories) or Kruskal-Wallis test (for comparison of 3 or more categories). Correlations were analyzed with the Spearman rank test. Student t test was used for the in vitro experiments when we compared 2 conditions. A probability value of Ͻ0.05 was considered significant.
Results
Early Growth Response-1 and Plaque Composition
EGR-1 was mainly expressed by SMCs ( Figure 1A ) and to a lesser extent by macrophages ( Figure 1D ). EGR-1 positively associated with a more fibrous plaque (Figure 2A ). Plaques with a high collagen content showed significantly higher EGR-1 levels compared with plaques with no or moderate collagen staining ( Figure 2B ). EGR-1 protein levels show significant positive correlation with intraplaque ␣-SMC actin levels (correlation coefficient: 0.280, Pϭ0.049; Figure 2C ). Plaques with positive SMCs/macrophages ratios showed higher EGR-1 expression when compared with plaques with higher macrophage content ( Figure 2D ). Furthermore, high EGR-1 levels positively correlated with low levels of the leukocyte chemoattractant interleukin-8 (correlation coefficient: Ϫ0.423, Pϭ0.00002; Figure 2E ). Interestingly, EGR-1 levels negatively correlated with the presence of intraplaque thrombi, indicative of unstable plaques ( Figure 2F ). Representative Western blots of our protein targets are depicted in Figure 2G .
Endoglin and Plaque Composition
Endoglin was expressed in some of the intraplaque vessels and SMCs within the lesion and to some extent by macrophages ( Figures 1B and E) . pSMAD expression was observed in SMCs, endothelial cells (not shown), and macrophages ( Figures 1C and F) . However, not all endothelial cells and SMCs expressed endoglin. Interestingly, endoglin expression was increased in plaques with more ␣-SMC actin (R 2 ϭ0.285; Pϭ0.035; Figure 2H ). Endoglin and macrophage content of the plaque did not correlate (Pϭ0.280, not shown). Endoglin expression was higher in plaques containing high levels of collagen ( Figure 2I ), indicative for a stable plaque less prone to rupture. Furthermore, endoglin positively correlated with less thrombi in the plaque ( Figure 2J ).
Intraplaque Transforming Growth Factor-␤ Signaling
The level of phosphorylated (p)-Smad within a lesion is as measure for TGF␤ signaling. Endoglin positively correlated with pSmad2 and pSmad3 (PϽ0.001 and Pϭ0.003, respectively; Figure 3A -B) levels in atherosclerotic plaques but did not correlate with pSmad1 (correlation coefficientϭ0.173; Pϭ0. 24 ), suggesting the presence of an endoglin-TGF␤-Smad2/3 signaling pathway within the lesion. Furthermore, pSmad2, but not pSmad1, was positively associated with SMCs (R 2 ϭ0.289; Pϭ0.03). In vitro, TGF␤ has been demonstrated to induce EGR-1 expression, which was mediated through pSmad2/3. 17 Accordingly, TGF␤ levels were associated with a significantly increased expression of EGR-1 ( Figure 3C ). In addition, EGR-1 expression was associated with TGF␤ signaling illustrated by increased pSmad2 (correlation coefficientϭ0.464, Pϭ0.001) as well as endoglin expression levels (correlation coefficientϭ0.363, Pϭ0.009; Figure 3D -E) but not pSmad1 ( Figure 3F ). Because TGF␤ signaling is influenced by endoglin, we analyzed the causal interaction between EGR-1 and endoglin. Endoglin-RNAi expressing vascular SMC showed no upregulation of EGR-1 expression after TGF␤ stimulation, whereas LacZ-transduced cells demonstrated a 1.3-fold increase ( Figure 4F ).
Transforming Growth Factor-␤, Endoglin, Early Growth Response-1, and Matrix Degradation
Because EMMPRIN and MMPs are important for extracellular matrix remodeling and regulated by TGF␤, we analyzed EMMPRIN expression and MMP-2 and MMP-9 activity. Interestingly, MMP-2 correlated with high endoglin and pSmad2 expression and we observed a trend between TGF␤ and MMP-2 ( Figure 5A-B ). pSmad1 levels negatively associated with TGF␤ and MMP-9 activity, (Pϭ0.017 and Pϭ0.014, respectively; Figure 5C -D). TGF␤ (Pϭ0.019), pSmad2 (Pϭ0.027), and endoglin strongly associated positively with EMMPRIN 45 kD (Pϭ0.008), which has been associated with a stable plaque phenotype, but not between pSmad1 and EMMPRIN 45kD ( Figure 5E-H) . pSmad1 levels were higher with decreased expression of EMMPRIN 58 kD. Furthermore, increased EGR-1 levels were associated with a significant increase in EMMPRIN 45kD ( Figure 5I ). There was no significant association between TGF␤ or EGR-1 with EMMPRIN 58 kD or MMP-2, nor did EGR-1 correlate with MMP-9 levels (not shown), suggesting that TGF␤ influences MMP activity through the 2 separate cascades, ALK5/Smad2/MMP2 and ALK1/Smad1/MMP9.
Endoglin Influences Smooth Muscle Cell Proliferation and Extracellular Matrix Metalloproteinase Protein Inducer Levels In Vitro
Endoglin knockdown in SMCs using RNAi did not affect TGF␤-induced Smad1/5 phosphorylation, but did inhibit pSmad2 ( Figure 4C ). On TGF␤ stimulation, Ki-67 expression Figure 2 (Continued) . ␣-smooth muscle cell actin levels (correlation coefficientϭ0.288, $ Pϭ0.049; C) and to a positive SMC/macrophage ratio (D). Interleukin-8 levels were significantly lower in plaques containing high levels of EGR-1 (E). The amount of intraplaque thrombus staining correlated negatively to EGR-1 levels (correlation coefficientϭϪ0.225, $ Pϭ0.022). Endoglin and ␣-smooth muscle cell actin levels correlated significantly ( $ Pϭ0.006, correlation coefficientϭ0.368; Figure 3H ). Endoglin expression was increased in plaques with high amounts of collagen, which points to a potential contributory role for endoglin toward stabilizing atherosclerotic plaques (Figure 3I) . We observed a negative association between endoglin expression and intraplaque thrombus (correlation coefficientϭϪ0.277, *Pϭ0.007; Figure 3J ). G, Representative Western blots. $ Spearman test. *Kruskal-Wallis test. was induced in LacZ-transduced cells indicating dividing cells, but not in endoglin knockdown cells ( Figure 4D PϽ0.05; nϭ3) . Analyzing EMMPRIN 45kD levels showed that although TGF␤ stimulation slightly increased EMMPRIN 45 kD levels, knockingdown endoglin resulted in severely reduced EMMPRIN 45 kD expression after TGF␤ addition ( Figure 4E ; Appendix, Supplement 1B). In the absence of endoglin, TGF␤ failed to induce procollagen I production. TGF␤ stimulation caused an average 1.44-fold (Ϯ0.096) increase in collagen I levels in LacZ-transduced SMCs, whereas there was an average 0.42fold decrease in procollagen I expression in endoglin knockdown cells (data not shown).
Correlation of Early Growth Response-1 With COL1A2-Promoter Activity
EGR-1 overexpression in human embryonic kidney-293 cells resulted in 2.4-fold increase in EGR-1 mRNA levels. Furthermore, EGR-1 transfection resulted in a significant dosedependent increase in COL1A2 promoter activity when compared with empty vector controls (Pϭ0.011; Figure 4G ).
Discussion
TGF␤ signaling, involving endoglin, pSmad2, and EGR-1, is associated with plaque stability. Besides significant correla- tions with a fibrous plaque phenotype and increased collagen levels, these factors were increased in SMC-rich plaques and correlated with decreased amounts of intraplaque thrombus. Previously, a small study reported higher TGF␤ levels to be associated with a stable plaque phenotype. 28 In these stable fibrous plaques, the expression of Smad2/3 was restricted to SMCs. 29 Furthermore, TGF␤ plasma levels may have prognostic significance in coronary artery disease. They are generally decreased in patients with coronary atherosclerosis and correlate inversely with the presence of myocardial ischemia. 30 -32 TGF␤ signals through phosphorylation of Smad proteins. Detection of pSmads showed active TGF␤ signaling within atherosclerotic lesions in SMC and endothelial cell. The correlations among endoglin, EGR-1, and pSmad2 suggests that endoglin modulates the TGF␤/Smad2 pathway within the plaque affecting expression of the down- Figure 6I ). $ Spearman test.
stream transcription factor EGR-1. Knocking-down endoglin expression reduces pSmad2 and EGR-1 levels, whereas it hardly affects pSmad1/5 levels, further indicating a relation between endoglin and TGF␤/Smad2/EGR-1 in atherosclerotic lesions. TGF␤ influences SMC proliferation, although its effect is not clear. TGF␤ stimulates vascular SMC proliferation at low concentrations 33 and knockdown of TGF␤ stimulates SMC growth. 34, 35 SMCs from normal arteries are growth-inhibited by TGF␤ in vitro; those derived from atherosclerotic and restenotic lesions are resistant to the antiproliferative effect of TGF␤. 36, 37 Furthermore, SMCs in stable lesions express more TGF␤ than in unstable lesions. 28 Also, SMCs within the fibrous cap differ in their responsiveness to TGF␤. 29 In contrast to SMCs of the normal vessel wall, endoglin expression is readily detectable in SMCs in atherosclerotic lesions. We show that endoglin is easily detectable in proliferating cultured SMCs. Endoglin knockdown resulted in decreased proliferation. Endoglin knockdown ameliorated the TGF␤induced inhibition in cell migration. Therefore, we suggest that endoglin-expressing SMCs within the plaque are resistant to TGF␤-induced growth inhibition and migration.
Santiago et al 19 found significantly decreased SMC proliferation and migration after blocking EGR-1 expression. We found a positive relation among endoglin, SMC content of the plaque, and EGR-1 expression suggesting a plaquestabilizing role for endoglin and EGR-1. EGR-1 inversely correlated with interleukin-8 expression and macrophage content. Additionally, both EGR-1 and endoglin negatively correlated with intraplaque thrombi, further arguing for a stabilizing role of EGR-1 and endoglin in atherosclerosis. Furthermore, collagen-rich plaques showed significantly higher EGR-1 expression. In vitro experiments confirmed the involvement of EGR-1 in increasing intraplaque collagen levels and is coherent with previous studies showing EGR-1-induced collagen production in fibroblasts. 17 Atherosclerotic plaque progression is a dynamic process with continuous remodeling of the extracellular matrix. MMPs, together with the inducer of MMP expression, EMMPRIN, mediate different processes within the atherosclerotic lesion, including matrix degradation, cell infiltration, and migration. TGF␤ is known to modulate the extracellular matrix and was found to inhibit EMMPRIN expression in human uterine fibroblasts. 38 We found a significant positive correlation between TGF␤ and EMMPRIN 45 kD and a negative correlation between TGF␤ and MMP-9, pointing toward a more stable plaque phenotype. Interestingly, although MMP-9 activity was associated with pSmad1, MMP-2 activity correlated with pSmad2. Endoglin expression correlated significantly with EMMPRIN expression. EMMPRIN stimulates MMP-9 in monocytes and MMP-2 in SMCs. 39 EMMPRIN 45 kD is expressed by plaque SMCs, and we previously showed that EMMPRIN 45 kD associated with SMC presence, MMP-2, and a fibrous plaque. We also observed a positive correlation between endoglin and MMP-2. TGF␤ and pSmad1 but not endoglin inversely correlated with EMMPRIN 58 kD and MMP-9, both associated with inflammatory unstable plaques. Furthermore, in vitro downregulation of endoglin in SMCs resulted in reduced EMMPRIN 45 kD after TGF␤ stimula-tion. Therefore, endoglin potentially stabilizes plaques through EMMPRIN 45 kD regulation, thereby modulating MMP-2 levels and matrix deposition. Induction of the TGF␤/ EGR-1 pathway not only enhances collagen synthesis, but also inhibits its degradation, resulting in an increased collagen deposition and thus a more stable fibrous cap.
TGF␤ appears to protect against the development of unstable atherosclerotic lesions by stimulating vascular SMC proliferation and modification of the extracellular matrix. Most of these effects appear to be mediated through the ALK5/TGF␤RII pathway and EGR-1. Expression of EGR-1 and endoglin are important for this stabilizing effect, resulting in increased SMC content, more fibrous lesions with increased collagen contents, and fewer intraplaque thrombi.
Conclusion
We propose a TGF␤ signaling pathway in atherosclerotic plaques, in which endoglin modulates the downstream effects of TGF␤ regulated by pSmad2/3 and increasing EGR-1 expression, resulting in increased collagen production, less matrix degradation, more SMC proliferation, and a reduction in inflammatory cells by inhibition of inflammatory cytokine production, in other words, in a more stable plaque phenotype. This nominates the TGF␤/endoglin/EGR-1 pathway as a potential new target for plaque stabilization therapy.
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